Top Telehealth Companies With Best Stability & Growth (720)

Market Expansion: Nationwide availability and a 2025 platform upgrade indicate broadened reach and capacity to serve patients across all states.

Product Line Growth: Expansion beyond obesity care into additional specialties and emphasis on in‑network options signal a widening portfolio and diversification of services.

Strong Hiring & Retention: Active postings for clinical and operational roles suggest ongoing headcount growth to support rising demand.

Profitability: The company reports achieving annual profitability in 2023 and sustaining it, with a 2025 Rule‑of‑40 score of 51% indicating efficiency in combining growth and margin. These signals point to durable unit economics rather than growth fueled by losses.

Strong Revenue Growth: Leadership cites roughly a 30% revenue CAGR over the past three years with acceleration into 2026. Continued national marketing and expanded booking channels align with ongoing top‑line momentum.

Strategic Partnerships: New integrations—such as Blue Shield of California’s member scheduling and Yelp’s real‑time booking—extend distribution beyond the core marketplace. These moves position the platform as access infrastructure across payer and high‑intent consumer surfaces.

Healthy Cash Flow: Operating and free cash flow both rose 19% in FY26, indicating robust cash generation alongside growth. Feedback suggests this provides flexibility to invest while maintaining resilience.

Strong Market Position & Advantage: The network reportedly includes more than 85% of U.S. physicians and set a record with over 800,000 active prescribers using workflow tools in Q4 FY26. This breadth of reach underpins monetization with core customers.

Innovation-Driven Growth: Nearly half of active prescribers used clinical AI features in Q4 FY26 as the company expands workflow/AI tools. Partnerships such as Aledade and Photon aim to deepen adoption and create future monetization paths.

Market Expansion: Public announcements indicate Sprinter expanded its Care+ home visits to roughly half the nation by February 2026, following growth from 18 states in mid-2025 with plans for 22 by late summer 2025. These disclosures point to steady footprint expansion into 2026.

Investor Backing & Capital Strength: The company closed a $55M Series B in May 2025, with total funding reported above $125M and an explicit mandate to expand team and footprint. Investor statements frame the raise as fuel for scaling operations and technology.

Strategic Partnerships: A regional Medicaid plan launched a Sprinter program for 1,900+ members as of January 1, 2025, illustrating payer uptake. Such partnerships are cited as drivers of volume and expansion.

Investor Backing & Capital Strength: Recent Series B and Series C rounds total significant capital, signaling strong investor confidence and providing resources to scale. The company earmarks this funding to expand its clinical network, AI initiatives, and partnerships.

Strong Revenue Growth: Consistent revenue expansion since launch is highlighted by nine‑figure revenue in 2024 and statements of rapid year‑over‑year growth. Reports also note the company reached profitability in 2025 alongside continued scaling.

Strategic Partnerships: Partnerships with hundreds of health plans, employers, and health systems expand distribution and indicate payer/provider acceptance. Named collaborations (e.g., a health‑system integration) and nationwide in‑network availability broaden access and patient reach.

Strong Revenue Growth: Repeated Inc. 5000 inclusion across 2021–2025 indicates multi‑year revenue expansion, with Inc. citing an 83% three‑year growth rate for the 2025 list. These external markers collectively point to sustained top‑line momentum.

Innovation-Driven Growth: AI‑driven launches in 2026 (RethinkBH AI Dashboard and Session Note AI) demonstrate ongoing product investment intended to enhance capability and adoption. Product momentum aligns with a growth posture centered on technology advancement.

Market Expansion: The August 2025 acquisition of Joshin expands the company’s neurodiversity and disability support offering, consistent with investing for growth. Scale indicators on the official site (e.g., Fortune 100 penetration and millions of lives served) further reflect broadening market reach.

Investor Backing & Capital Strength: Back-to-back late-stage funding rounds in 2026 with a significant valuation step-up indicate strong access to capital and investor conviction. Participation from well-known venture and strategic investors underscores financing momentum.

Strong Revenue Growth: Company disclosures around the 2026 raises cite rapid year-over-year revenue gains and a growing recurring revenue base. The pace is described as compounding across multiple years.

Market Expansion: Public announcements reference service to millions of members across hundreds of organizations and recent agreements with health systems and plans. These signals point to a widening commercial footprint for an employer-focused private company.

Market Expansion: Company updates show nationwide clinical coverage, international deployments, and active presence at major payer conferences in 2026. Covered‑lives claims and marketplace availability indicate broadened reach and distribution.

Strategic Partnerships: Partnerships with Google Cloud, Horizon, and new collaborators in musculoskeletal care and Brazil suggest strong enterprise channels and distribution leverage. Advisory board additions with senior leaders from prominent health organizations reinforce enterprise go‑to‑market scale.

Product Line Growth: Launches of the end‑to‑end Navigator platform and AI agents for wellness and behavioral health since 2024–2025 reflect expanding offerings. These additions align with payer needs for unified, AI‑assisted navigation across benefits, care management, and behavioral health.

Strong Hiring & Retention: Active hiring signals are evident with multiple recent postings across Operations, Engineering, Product, RCM, and Partnerships and a visible “We’re Hiring!” banner. Feedback suggests team size and social followership on LinkedIn are consistent with recent headcount expansion.

Market Expansion: The company markets Medicare-covered virtual psychotherapy “across all 50 states,” indicating a national footprint rather than a limited pilot. Self-described service to “thousands of patients” across many states further reinforces expanding reach.

Innovation-Driven Growth: The organization emphasizes an AI-native platform with real-time clinical insights and clinical copilots to scale care delivery and efficiency. This technology-forward posture supports growth in virtual operations for older adults.

Investor Backing & Capital Strength: Recent financing rounds, including a sizable Series B and an additional credit facility, indicate strong investor confidence and ample runway. The capital is explicitly tied to hiring, go‑to‑market, and product expansion plans across 2024–2026 communications.

Product Line Growth: Ongoing launches such as AI‑powered Claims Analytics and “Zoe for HR” suggest continued investment in expanding the platform. Added capabilities like a cash‑pay network and pharmacy‑related tools point to a broadened offering beyond core navigation.

Strategic Partnerships: Partnerships with platforms and channels such as TriNet, Workday Wellness, PrismHR, and benefit alliances indicate growing distribution reach. Event participation and partner documentation suggest active customer acquisition across employer and PEO ecosystems.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2024–2025, led by top VCs with broad participation from life/insurance strategics, indicate robust capital support for scaling. Feedback suggests this financing underpins product development and market expansion plans into 2026.

Strategic Partnerships: Named relationships with several top U.S. life insurers and new 2026 collaborations in Canada and the U.K. signal embedded distribution and enterprise validation. Company and partner announcements throughout 2025–2026 point to a steady cadence of carrier and bank integrations.

Market Expansion: Expansion from a U.S. focus into Canada and the U.K., alongside multiple 2026 partner rollouts, broadens the company’s geographic footprint. Feedback suggests these moves are increasing coverage to larger populations via insurer and financial channels.

Strong Revenue Growth: Independent private‑market researchers indicate annualized revenue rose meaningfully in 2024, showing a clear upturn driven by GLP‑1 obesity care. This reacceleration suggests business momentum returned after earlier slowdowns.

Strategic Partnerships: In April 2025, Novo Nordisk chose Ro to sell Wegovy at a lower cash price via Novo’s pharmacy channel, likely funneling incremental demand to the platform. Ongoing promotions and subscription‑style pricing through this channel indicate continued partner alignment.

Product Line Growth: Ro launched and scaled a GLP‑1 weight‑management program and published weight‑loss and lab‑improvement results supporting ongoing use and cross‑sell within its telehealth and pharmacy stack. Integration with manufacturer channels further enhanced program reach and conversion.

Strong Revenue Growth: Independent market research estimates indicate annualized revenue roughly doubled in 2024, pointing to rapid topline expansion into 2025. This trajectory aligns with other scale markers like cumulative sessions growth.

Market Expansion: Company materials describe nationwide therapy and psychiatry availability and 10M+ cumulative sessions by mid‑2026, indicating expanding reach and utilization. Press mentions of 21,000+ licensed providers with next‑day access further underscore capacity growth.

Strategic Partnerships: Recent references to integrations with major insurers and health‑system/employer channels (e.g., Kaiser regions, Stanford Health Care Alliance, Amazon programs) suggest deepening distribution. Active hiring for partnership roles and multiple plan collaborations reinforce go‑to‑market scaling.

Investor Backing & Capital Strength: Funding announcements show Marble Health raised a $15.5M Series A in October 2025 led by Costanoa with participation from Town Hall Ventures and Khosla Ventures, signaling strong investor support. Company and investor communications indicate this capital is earmarked to scale operations, expand partnerships, and grow the team.

Market Expansion: Company updates indicate launches beyond New York into states like Ohio and New Jersey, pointing to a widening geographic footprint. Public materials also highlight school partnerships and rising therapy-session volumes since launch, consistent with expansion.

Strong Hiring & Retention: Open roles across growth, operations, and product on company and third‑party job boards indicate active team growth. Leadership posts describe go‑to‑market hiring momentum ahead of school years, suggesting sustained scaling efforts.

Market Expansion: The company continues to open new clinics across NH, ME, and MA, with recent ribbon-cuttings (e.g., Hudson, MA; Farmington, ME) and a West Lebanon, NH site slated for summer 2026. Industry tallies and company materials place the footprint around 50 urgent care sites with additional openings planned.

Investor Backing & Capital Strength: Bain Capital acquired a controlling stake in 2021 and positioned the investment to fund continued expansion in New England and underserved areas. This institutional backing supports ongoing site development and service-line buildout.

Diversified Revenue Streams: The organization is expanding beyond urgent care into Advanced Primary Care, virtual care, and employer services, with new primary care clinics (e.g., Bangor, ME) and payer arrangements (e.g., in‑network for Anthem in Bangor) broadening its revenue mix.